Detection of bcr/abl fusion gene changes in patients with chronic myeloid leukemia after allo-HSCT by real-time quantitative reverse transcription polymerase chain reaction and its significance.
- Author:
Mei XUE
1
;
Heng-Xiang WANG
;
Lian-Ning DUAN
;
Hong-Min YAN
;
Ling ZHU
;
Jing LIU
;
Li DING
Author Information
1. Department of Hematology, Air Force General Hospital, Beijing 100036, China. xue_mei882000@yahoo.com.cn
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Female;
Fusion Proteins, bcr-abl;
genetics;
Genes, abl;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
genetics;
surgery;
Male;
Middle Aged;
Reverse Transcriptase Polymerase Chain Reaction;
Young Adult
- From:
Journal of Experimental Hematology
2008;16(6):1350-1353
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to detect the changes of bcr/able gene level in ph+ CML patients at different stages after allo-HSCT by real-time quantitative PCR and to evaluate the significance of this detection. The serial detection of bcr/abl fusion gene levels in 21 cases of CML treated with allo-HSCT was performed by RQ-PCR. The results showed that the bcr/able fusion gene could not be detected in 7 out 21 CML cases with positive fusion gene after allo-HSCT, while the bcr/abl fusion gene of different levels could be detected in 14 cases within 1-6 months. Dynamic detection indicated that the bcr/abl fusion gene levels in 9 cases were lower with relative value 0.0074%-0.088% and then could not be detected within 3-7 months after allo-HSCT. The bcr/abl fusion gene levels in 5 cases diagnosed as molecular relapse were between 0.077%-75%. The bcr/abl fusion gene levels in 1 out of 5 cases were 0.95%, 1.5%, and 0.16% in month 1, 2 and 3, respectively, and turned to negative in the month 4 without any treatment after allo-HSCT. 2 cases received the donor peripheral blood stem cell infusion, and then their bcr/abl mRNA levels could not be detected in bone marrow. Another 2 cases developed to the hematologic relapse, 1 out of 2 cases reached CR again after infusion of donor peripheral blood stem cells and chemotherapy, the other one died. It is concluded that serial quantifications of bcr/abl mRNA levels by RQ-PCR are reliable and can be used to detect the MRD, to monitor the outcome and to predict the relapse.
